Japan has just made history by approving the world’s first stem-cell treatments for Parkinson’s disease and severe heart failure.
Sumitomo Pharma’s Amchepry, a treatment for Parkinson’s, uses induced pluripotent stem (iPS) cells to replace damaged dopamine-producing neurons in the brain.
This breakthrough could benefit millions worldwide, as Parkinson’s affects around 10 million people globally.
The treatment involves transplanting stem-cell-derived dopamine precursor cells into the brain, which has shown promising results in a clinical trial.
Seven Parkinson’s patients aged 50-69 received the treatment, and four showed significant improvement in symptoms with no major adverse effects over two years.
Japan’s health ministry also approved ReHeart, developed by Cuorips, which uses heart muscle sheets to promote new blood vessel growth and restore heart function in patients with severe heart failure.
These therapies are expected to reach patients this summer, marking a significant milestone in regenerative medicine.
Health Minister Kenichiro Ueno hopes this breakthrough will bring relief to patients worldwide.
